Nine analysts now watch Vera Therapeutics, a small biotech company working on serious immune-driven kidney disease, and most of them lean toward buying its shares, with an average price target of $63 set against a stock trading near $29. The gap between that hopeful consensus and the market price reflects a familiar tension in early drug development: investors are betting on a single lead candidate, atacicept, that has not yet proven itself in late-stage trials. Its losses, its strong cash position, and its growing institutional backing all sit side by side, leaving the company's future to be
Vera Therapeutics Draws $63 Average Analyst Target, Implying Steep Upside From $29 Share Price
Analysts see $63. The stock opened at $29.06.
Mark
Why does a $63 average target matter when the stock is at $29?
Mimi
It shows how far analysts' expectations sit from the market price. Seven of nine rate it a buy, and that gap is the headline.
Mark
What is the company actually selling?
Mimi
Nothing yet. It is clinical stage. Atacicept is in Phase III for IgA nephropathy and Phase II for lupus nephritis.
Luke
So the targets rest on trial outcomes that haven't happened. The article doesn't say how each analyst got their number.
Mark
The last earnings were a miss, though.
Mimi
A $1.20 loss per share against an expected $0.82 loss. Still, the stock is above its 50-day and 200-day averages.
Luke
Worth noting JPMorgan cut its target from $56 to $53 in August. The $63 is an average, and we only see one revision here.
Mark
And the institutional buying?
Mimi
Several funds added shares, and institutions hold 99.21% of the stock.
Luke
Those are filings from the fourth and first quarters, so they're dated. They don't tell us what those funds hold today.
Il Polso
- Seven of nine analysts say buy, yet the stock opened at $29.06, far below the $63 average target that many expect it to climb toward.
- Vera's latest quarterly loss of $1.20 per share missed estimates by $0.38, sharpening questions about how long the company can keep spending before revenue arrives.
- The company is pinning its hopes on atacicept, now in a Phase III trial for IgA nephropathy, a step that will decide whether the bet pays off.
- Institutional investors hold nearly all the shares and several have recently added to their positions, suggesting confidence is quietly building despite the losses.
- Trial results and the next earnings report are the moments that will show whether the stock's recovery above its moving averages can hold.
Nine analysts now watch Vera Therapeutics, a small biotech company working on serious immune-driven kidney disease, and most of them lean toward buying its shares, with an average price target of $63 set against a stock trading near $29. The gap between that hopeful consensus and the market price reflects a familiar tension in early drug development: investors are betting on a single lead candidate, atacicept, that has not yet proven itself in late-stage trials. Its losses, its strong cash position, and its growing institutional backing all sit side by side, leaving the company's future to be settled by data still to come.
Nine brokerages currently follow Vera Therapeutics, and together they have settled on a consensus rating of "Moderate Buy." Seven of the nine recommend buying the stock, and two advise holding. Their average twelve-month price target stands at $63.00, a figure that sits well above where the shares actually trade.
VERA opened at $29.06, giving the company a market value of about $1.85 billion. The shares are trading above both their fifty-day and two-hundred-day averages, though over the past year they have swung between $18.53 and $51.61. The recent analyst activity is mixed in tone: JPMorgan trimmed its target from $56 to $53 while keeping an overweight rating, Wolfe Research held a peer-perform view, and Cantor Fitzgerald reaffirmed its overweight stance in mid-September.
The company's most recent quarter brought disappointment. Vera lost $1.20 per share, worse than the expected loss of $0.82, and analysts now forecast a loss of $2.89 per share for the full year. Its balance sheet, however, carries little debt and strong liquidity, and institutional investors own almost all of the stock, with several recently increasing their stakes.
Everything turns on atacicept, the company's lead candidate. The treatment is in a Phase III trial for IgA nephropathy and a Phase II trial for lupus nephritis. Results from those studies and the next earnings report will reveal whether the optimism behind the $63 target has solid ground beneath it.
Nine brokerages currently cover Vera Therapeutics, and together they have landed on a consensus rating of "Moderate Buy," according to MarketBeat data republished by ETF Daily News. Seven of the nine rate the stock a buy. Two rate it a hold. The average 12-month price objective among analysts who have issued ratings in the past year is $63.00.
That figure sits well above where the stock trades. VERA opened at $29.06 on Friday, which gives the company a market cap of $1.85 billion. The price is above both its fifty-day simple moving average of $23.00 and its 200-day average of $23.04. Over the past twelve months the shares have ranged from a low of $18.53 to a high of $51.61.
Several of the individual calls are dated. Scotiabank reissued an "outperform" rating on Tuesday, June 3rd, and Guggenheim reissued a "buy" the same day. Wolfe Research reissued a "peer perform" rating on Monday, August 4th. JPMorgan Chase & Co. cut its price objective from $56.00 to $53.00 on Thursday, August 7th, while keeping an "overweight" rating. Cantor Fitzgerald is the most recent, reissuing an "overweight" rating on Thursday, September 18th.
The company's last quarterly report came on Tuesday, August 5th. Vera posted a loss of $1.20 per share, worse than the consensus estimate of a $0.82 loss, a miss of $0.38. In the same quarter a year earlier, the loss was $0.62 per share. Analysts expect a loss of $2.89 per share for the current fiscal year. The stock carries a price-to-earnings ratio of -8.12 and a beta of 1.17. Its balance sheet shows a current ratio and quick ratio of 17.03 each, and a debt-to-equity ratio of 0.16.
Institutional investors own 99.21% of the stock, and several have recently added to their positions. Ameriprise Financial raised its stake by 31.7% in the fourth quarter, buying 7,227 shares to hold 30,021 worth $1,270,000. UBS Asset Management Americas increased its holding by 30.1%, adding 18,532 shares for a total of 80,106 valued at $3,388,000. California State Teachers Retirement System grew its position by 19.9%, buying 6,749 shares to reach 40,640 worth $1,719,000.
Two more filings cover the first quarter. GAMMA Investing LLC raised its stake by 1,779.1%, adding 7,846 shares to hold 8,287 worth $199,000. Rhumbline Advisers added 4,600 shares, a 7.9% increase, bringing its holding to 63,189 shares worth $1,518,000.
Vera is a clinical-stage biotechnology company focused on treatments for serious immunological diseases. Its lead candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. It is in a Phase III trial for immunoglobulin A nephropathy and in a Phase II trial for lupus nephritis. Trial results and the next earnings report are the events to watch.
Citazioni salienti
JPMorgan lowered its price objective from $56.00 to $53.00 and kept an overweight rating.— JPMorgan Chase & Co., report of August 7th
Vuoi la storia completa?
Leggi l'originale su ETF Daily News ↗
Economy & Finance